Arkansas Research Trials

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)8 trials
• Chronic spontaneous urticaria2 trials
• Hidradenitis suppurativa2 trials
• Lupus (SLE)1 trial
• Melanoma1 trial

Phase

• Phase 310 trials
• Phase 12 trials
• Phase 1/21 trial
• Phase 21 trial

Status

• Recruiting5 trials
• Active, not recruiting4 trials
• Completed4 trials
• Enrolling by invitation1 trial

Lead sponsor

• Eli Lilly and Company3 trials
• Novartis Pharmaceuticals3 trials
• Incyte Corporation2 trials
• Pfizer2 trials
• Regeneron Pharmaceuticals2 trials
• and 2 more

Running trials

• Recruiting

  An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

  NCT07665437· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Shawna Owens

• Recruiting

  First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

  NCT07527923· Phase 1· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

  NCT06807281· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

  NCT06807268· Phase 3· Pfizer· Source

• Active, not recruiting

  A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

  NCT06799000· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

  NCT06585410· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

  NCT06055361· Phase 1· Brexogen Inc.· Source

  Contact: Shawna S Owens

• Enrolling by invitation

  A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05735483· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

  NCT05513001· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05559359· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)4 recruiting
• Hidradenitis suppurativa1 recruiting
• Melanoma1 recruiting

Closed trials

• Completed

  Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

  NCT05936567· Phase 2· Incyte Corporation· Source

• Completed

  A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

  NCT05638802· Phase 1/2· Daiichi Sankyo· Source

• Completed

  Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

  NCT05456529· Phase 3· Incyte Corporation· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source